Spyre Therapeutics, Inc. (SYRE)

Market Cap	3.39B +180.1%
Revenue (ttm)	n/a
Net Income	-126.54M
EPS	-1.98
Shares Out	78.54M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,278,268
Open	37.82
Previous Close	37.81
Day's Range	37.81 - 43.56
52-Week Range	10.91 - 43.56
Beta	3.16
Analysts	Strong Buy
Price Target	55.57 (+28.6%)
Earnings Date	Feb 19, 2026

About SYRE

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the α4β7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn’s disease); and SPY002 and SPY072 – anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also develo...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 7, 2016
• Employees: 95
• Stock Exchange: NASDAQ
• Ticker Symbol: SYRE
• Website: https://www.spyre.com

Analyst Summary

According to 7 analysts, the average rating for SYRE stock is "Strong Buy." The 12-month stock price target is $55.57, which is an increase of 28.60% from the latest price.

Price Target

$55.57

(28.60% upside)

Analyst Consensus: Strong Buy